Crispr Therapeutics Ag Stock Cash Flow From Operations
| 1CG Stock | 40.80 0.00 0.00% |
CRISPR Therapeutics AG fundamentals help investors to digest information that contributes to CRISPR Therapeutics' financial success or failures. It also enables traders to predict the movement of CRISPR Stock. The fundamental analysis module provides a way to measure CRISPR Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to CRISPR Therapeutics stock.
CRISPR |
CRISPR Therapeutics AG Company Cash Flow From Operations Analysis
CRISPR Therapeutics' Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current CRISPR Therapeutics Cash Flow From Operations | (495.74 M) |
Most of CRISPR Therapeutics' fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, CRISPR Therapeutics AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
| Competition |
In accordance with the recently published financial statements, CRISPR Therapeutics AG has (495.74 Million) in Cash Flow From Operations. This is much lower than that of the sector and significantly lower than that of the Cash Flow From Operations industry. The cash flow from operations for all Germany stocks is notably higher than that of the company.
CRISPR Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CRISPR Therapeutics' direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of CRISPR Therapeutics could also be used in its relative valuation, which is a method of valuing CRISPR Therapeutics by comparing valuation metrics of similar companies.CRISPR Therapeutics is currently under evaluation in cash flow from operations category among its peers.
CRISPR Fundamentals
| Current Valuation | 2.16 B | |||
| Price To Book | 6.67 X | |||
| Price To Sales | 1,731 X | |||
| Revenue | 436 K | |||
| EBITDA | (648.99 M) | |||
| Net Income | (650.17 M) | |||
| Cash Flow From Operations | (495.74 M) | |||
| Market Capitalization | 4.99 B | |||
| Total Asset | 2.24 B | |||
| Net Asset | 2.24 B |
About CRISPR Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CRISPR Therapeutics AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CRISPR Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CRISPR Therapeutics AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for CRISPR Stock Analysis
When running CRISPR Therapeutics' price analysis, check to measure CRISPR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CRISPR Therapeutics is operating at the current time. Most of CRISPR Therapeutics' value examination focuses on studying past and present price action to predict the probability of CRISPR Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CRISPR Therapeutics' price. Additionally, you may evaluate how the addition of CRISPR Therapeutics to your portfolios can decrease your overall portfolio volatility.